PRM142 - QUANTITATIVE BENEFIT-RISK MODELLING OF BIOSIMILARS- A CASE STUDY OF INFLIXIMAB IN CROHN’S DISEASE.
Oct 1, 2018, 00:00
10.1016/j.jval.2018.09.2262
https://www.valueinhealthjournal.com/article/S1098-3015(18)35564-5/fulltext
Title :
PRM142 - QUANTITATIVE BENEFIT-RISK MODELLING OF BIOSIMILARS- A CASE STUDY OF INFLIXIMAB IN CROHN’S DISEASE.
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(18)35564-5&doi=10.1016/j.jval.2018.09.2262
First page :
Section Title :
Open access? :
No
Section Order :
1616